Research programme: caspase-8 inhibitors - Apoxis
Latest Information Update: 28 Jun 2004
At a glance
- Originator Apoxis
- Class
- Mechanism of Action Caspase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allotransplant rejection
Most Recent Events
- 28 Jun 2004 Discontinued - Preclinical for Allotransplant rejection in Switzerland (unspecified route)
- 02 Jul 2003 Preclinical trials in Allotransplant rejection in Switzerland (unspecified route)